Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in OncologyJohn A. Thompson, Jillian L. Scavone, Brianna Hoffner et al.|Journal of the National Comprehensive Cancer Network|2019Cited by 560
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020John A. Thompson, Anita M. Engh, Bryan J. Schneider et al.|Journal of the National Comprehensive Cancer Network|2020Cited by 484
Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institutionMabel Ryder, James A. Fagin|Endocrine Related Cancer|2014Cited by 439
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in OncologyJohn A. Thompson, Lisa Hang, Bryan J. Schneider et al.|Journal of the National Comprehensive Cancer Network|2022Cited by 416
Genetic and Pharmacological Targeting of CSF-1/CSF-1R Inhibits Tumor-Associated Macrophages and Impairs BRAF-Induced Thyroid Cancer ProgressionMabel Ryder, James A. Fagin|PLoS ONE|2013Cited by 135